

CLAIMS

1. A human antibody that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet agglutination independently, or an
5 active-fragment thereof.

2. A human antibody that specifically binds to human platelet membrane glycoprotein VI and suppresses collagen-mediated human platelet agglutination by in vivo administration, or an active-fragment thereof.

3. A human antibody that specifically binds to human GPVI and has any one or
10 more functions of the following functions: specifically inhibiting a binding of GPVI on the platelet to collagen; disappearing a functional GPVI on the platelet; or decreasing or deleting a collagen-mediated agglutinability of the human platelet by preliminarily contacting with the human platelet, or an active-fragment thereof.

4. A human antibody that specifically binds to human platelet membrane glycoprotein VI, suppresses a collagen-mediated agglutinability of the human platelet and does not induce a human platelet agglutination independently, or an active-fragment thereof.
15

5. An antibody or an active fragment thereof, wherein VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 98, SEQ ID NO: 99 and SEQ ID NO: 100, respectively; or VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
20

6. A cell that produces the antibody of claims 1 through 5 or an active fragment thereof.
25

7. A polynucleotide that comprises a base sequence encoding a H chain and/or L chain of the antibody of claims 1 through 5 or an active fragment thereof.

8. A pharmaceutical composition that comprises the antibody of claims 1 through 4 or an active fragment thereof as an active ingredient.

9. A method for producing a recombinant human-human chimeric antibody